• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/16/21 10:26:22 AM ET
    $FPRX
    Major Pharmaceuticals
    Health Care
    Get the next $FPRX alert in real time by email
    SC 13G 1 form-sc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934 (Amendment No._N/A_)*

     

    Five Prime Therapeutics, Inc.

     

    (Name of Issuer)

     

    Common Stock

     

    (Title of Class of Securities)

     

    33830X104

     

    (CUSIP Number)

     

    December 31, 2020

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [X] Rule 13d-1(b)

     

    [_] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP No.

    33830X104

     

     

    1. NAME OF REPORTING PERSONS
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
      RTW Investments, LP
       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
       
          (a) [  ]
          (b) [X]
       
    3. SEC USE ONLY
       
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Delaware, United States of America
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
       
    5. SOLE VOTING POWER
       
      0 
       
    6. SHARED VOTING POWER
       
     

    2,515,788*

       
    7. SOLE DISPOSITIVE POWER
       
      0
       
    8. SHARED DISPOSITIVE POWER
       
     

    2,515,788*

       
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     

    2,515,788*

       
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
          [  ]
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     

    5.73%*

       
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      PN, OO, IA

     

     
     

     

    CUSIP No.

    33830X104

     

     

    1. NAME OF REPORTING PERSONS
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
      Roderick Wong
       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
       
          (a) [  ]
          (b) [X]
           
    3. SEC USE ONLY
       
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
       
      United States of America
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
       
    5. SOLE VOTING POWER
       
      0
       
    6. SHARED VOTING POWER
       
     

    2,515,788*

       
    7. SOLE DISPOSITIVE POWER
       
      0
       
    8. SHARED DISPOSITIVE POWER
       
     

    2,515,788*

       
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     

    2,515,788*

       
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
          [  ]
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     

    5.73%

       
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      IN, HC

     

     
     

     

    Item 1. (a).

    Name of Issuer:

     

    Five Prime Therapeutics, Inc.

         
      (b). Address of issuer’s principal executive offices:
         
       

    111 Oyster Point Boulevard

    South San Francisco, CA 94080

         
    Item 2. (a). Name of person filing:
         
        RTW Investments, LP
        Roderick Wong
         
      (b). Address or principal business office or, if none, residence:
         
        RTW Investments, LP
        40 10th Avenue
        Floor 7
        New York, New York 10014
         
        Roderick Wong
        c/o RTW Investments, LP
       

    40 10th Avenue

        Floor 7
        New York, New York 10014
         
      (c). Citizenship:
         
        RTW Investments, LP – Delaware
        Roderick Wong – United States of America
         
      (d). Title of class of securities:
         
        Common Stock
         
      (e). CUSIP No.:
         
        33830X104

     

     
     

     

    Item 3. If This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

      RTW Investments, LP:
         
      (a) [  ] Broker or Dealer Registered Under Section 15 of the Act (15 U.S.C. 78o)
      (b) [  ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c)
      (c) [  ] Insurance Company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c)
      (d) [  ] Investment Company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)
      (e) [X] Investment Adviser in accordance with § 240.13d-1(b)(1)(ii)(E)
      (f) [  ] Employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F)
      (g) [  ] Parent Holding Company or control person in accordance with §240.13d-1(b)(ii)(G)
      (h) [  ] Savings Association as defined in §3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813)
      (i) [  ] Church plan that is excluded from the definition of an investment company under §3(c)(15) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)
      (j) [  ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J)
      (k) [  ] Group, in accordance with §240.13d-1(b)(ii)(K) (a) [_]
         
      Roderick Wong:
         
      (a) [  ] Broker or Dealer Registered Under Section 15 of the Act (15 U.S.C. 78o)
      (b) [  ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c)
      (c) [  ] Insurance Company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c)
      (d) [  ] Investment Company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)
      (e) [  ] Investment Adviser in accordance with § 240.13d-1(b)(1)(ii)(E)
      (f) [  ] Employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F)
      (g) [X] Parent Holding Company or control person in accordance with §240.13d-1(b)(ii)(G)
      (h) [  ] Savings Association as defined in §3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813)
      (i) [  ] Church plan that is excluded from the definition of an investment company under §3(c)(15) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)
      (j) [  ]   A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J)
      (k) [  ] Group, in accordance with §240.13d-1(b)(ii)(K) (a) [_]

     

    Item 4. Ownership.
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
         
      (a) Amount beneficially owned:
         
        RTW Investments, LP – 2,515,788*
        Roderick Wong – 2,515,788*
         
      (b) Percent of class:
         
        RTW Investments, LP – 5.73%*
        Roderick Wong – 5.73%*
         
      (c) Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote
           
          RTW Investments, LP – 0
          Roderick Wong – 0
           
        (ii) Shared power to vote or to direct the vote
           
          RTW Investments, LP – 2,515,788*
          Roderick Wong – 2,515,788*
           
        (iii) Sole power to dispose or to direct the disposition of
           
          RTW Investments, LP – 0
          Roderick Wong – 0
           
        (iv) Shared power to dispose or to direct the disposition of
           
          RTW Investments, LP –2,515,788*
          Roderick Wong – 2,515,788*

     

     

     

    * The shares of common stock (the “Shares”), of Five Prime Therapeutics, Inc. (the “Company”), reported herein are held by one or more private funds (together the “Funds”), which are managed by RTW Investments, LP (the “Adviser”). The Adviser, in its capacity as the investment manager of Funds, has the power to vote and the power to direct the disposition of all Shares held by the Funds. Accordingly, for the purposes of Reg. Section 240.13d-3, the Adviser may be deemed to beneficially own an aggregate of 2,515,788 Shares, or 5.73% of the Shares issued and outstanding as of November 13, 2020. Roderick Wong is the Managing Partner of the Adviser. The beneficial ownership percentage reported herein is based on 43,900,167 Shares issued and outstanding as of November 13, 2020, as disclosed in the Company’s Prospectus, as filed with the Securities and Exchange Commission on November 13, 2020. This report shall not be deemed an admission that the Adviser, the Funds or any other person is the beneficial owner of the securities reported herein for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the reporting persons herein disclaims beneficial ownership of the Shares reported herein except to the extent of the reporting person’s pecuniary interest therein.

     

     

     

     
     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].

       
      N/A
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
     

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

       
      N/A
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
     

    If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

       
      N/A
       
    Item 8. Identification and Classification of Members of the Group.
       
     

    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.

       
      N/A
       
    Item 9. Notice of Dissolution of Group.
       
     

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

       
      N/A
       
    Item 10. Certification.
       
     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 16, 2021

       
         
      RTW Investments, LP
         
      By: /s/ Roderick Wong
        Roderick Wong, Managing Partner
         
      Roderick Wong
         
      By: /s/ Roderick Wong
        Roderick Wong, Individually

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

     

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

       

     

    Get the next $FPRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FPRX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FPRX
    Financials

    Live finance-specific insights

    See more
    • Amgen Successfully Completes Acquisition Of Five Prime Therapeutics

      THOUSAND OAKS, Calif., April 16, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for $38.00 per share in cash. The aggregate consideration to be paid by Amgen to complete the tender offer and the subsequent merger is approximately $1.9 billion without giving effect to related transaction fees and expenses. "Five Prime fits squarely within Amgen's leading oncology portfolio and includes bemarituzumab, a Phase 3 tr

      4/16/21 8:25:00 AM ET
      $FPRX
      $AMGN
      Major Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $FPRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Apexigen Announces Appointment of Francis Sarena as Chief Operating Officer

      SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced the appointment of Francis Sarena as Chief Operating Officer. Mr. Sarena will be responsible for leading strategic operations, driving business development, overseeing finance and investor relations and optimizing organizational functions. "We are thrilled to welcome Francis, an accomplished industry veteran, during this important phase of Apexigen's evolution," said Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer of Apexigen. "His deep biopharmaceut

      1/4/22 8:00:00 AM ET
      $FACT
      $FPRX
      $PDLI
      Major Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Amgen Successfully Completes Acquisition Of Five Prime Therapeutics

      THOUSAND OAKS, Calif., April 16, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for $38.00 per share in cash. The aggregate consideration to be paid by Amgen to complete the tender offer and the subsequent merger is approximately $1.9 billion without giving effect to related transaction fees and expenses. "Five Prime fits squarely within Amgen's leading oncology portfolio and includes bemarituzumab, a Phase 3 tr

      4/16/21 8:25:00 AM ET
      $FPRX
      $AMGN
      Major Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Five Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call

      SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX) announced today that it has canceled its fourth quarter and full year 2020 earnings conference call, which was previously scheduled for Wednesday, March 10, 2021 at 1:30 p.m. PT / 4:30 p.m. ET. The cancellation is the result of the company’s announcement on March 4, 2021 that it has entered into an agreement under which Amgen Inc. will acquire Five Prime Therapeutics. Five Prime will issue its fourth quarter and full-year 2020 financial results in its Form 10-K that it will file with the Securities and Exchange Commission. About Five Prime Therapeutics Five Prime is a clinical stage biotech

      3/9/21 5:00:00 PM ET
      $FPRX
      Major Pharmaceuticals
      Health Care

    $FPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim resumed coverage on Five Prime Therapeutics with a new price target

      Guggenheim resumed coverage of Five Prime Therapeutics with a rating of Neutral and set a new price target of $38.00

      3/15/21 8:09:30 AM ET
      $FPRX
      Major Pharmaceuticals
      Health Care
    • Jefferies Financial Group resumed coverage on Five Prime Therapeutics with a new price target

      Jefferies Financial Group resumed coverage of Five Prime Therapeutics with a rating of Hold and set a new price target of $38.00

      3/10/21 8:10:17 AM ET
      $FPRX
      Major Pharmaceuticals
      Health Care
    • Five Prime Therapeutics downgraded by Guggenheim with a new price target

      Guggenheim downgraded Five Prime Therapeutics from Buy to Neutral and set a new price target of $38.00

      3/9/21 6:56:49 AM ET
      $FPRX
      Major Pharmaceuticals
      Health Care

    $FPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Sarena Francis Willard received a gift of 2,385 units of Common Stock, was granted 66,000 units of Common Stock, disposed of $6,530,414 worth of Common Stock back to the company (171,853 units at $38.00) and gifted 20,459 units of Common Stock, decreasing direct ownership by 100% to 0 units to satisfy withholding obligation

      4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)

      4/19/21 8:04:26 PM ET
      $FPRX
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Smith David V was granted 66,000 units of Common Stock and disposed of $5,279,986 worth of Common Stock back to the company (138,947 units at $38.00) , decreasing direct ownership by 100% to 0 units to satisfy tax liability

      4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)

      4/19/21 7:57:02 PM ET
      $FPRX
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Collins Helen Louise disposed of $5,150,786 worth of Common Stock back to the company (135,547 units at $38.00) , gifted 8,085 units of Common Stock and was granted 66,000 units of Common Stock, decreasing direct ownership by 100% to 0 units to satisfy tax liability

      4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)

      4/19/21 7:53:58 PM ET
      $FPRX
      Major Pharmaceuticals
      Health Care

    $FPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Five Prime Therapeutics, Inc.

      SC 13D - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Subject)

      3/15/21 6:33:20 AM ET
      $FPRX
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Subject)

      3/8/21 4:54:44 PM ET
      $FPRX
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed

      SC 13G - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Subject)

      3/1/21 5:00:03 PM ET
      $FPRX
      Major Pharmaceuticals
      Health Care

    $FPRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Apexigen Announces Appointment of Francis Sarena as Chief Operating Officer

      SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced the appointment of Francis Sarena as Chief Operating Officer. Mr. Sarena will be responsible for leading strategic operations, driving business development, overseeing finance and investor relations and optimizing organizational functions. "We are thrilled to welcome Francis, an accomplished industry veteran, during this important phase of Apexigen's evolution," said Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer of Apexigen. "His deep biopharmaceut

      1/4/22 8:00:00 AM ET
      $FACT
      $FPRX
      $PDLI
      Major Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $FPRX
    SEC Filings

    See more
    • SEC Form SC 13G/A filed by Five Prime Therapeutics, Inc. (Amendment)

      SC 13G/A - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Subject)

      5/17/21 4:34:51 PM ET
      $FPRX
      Major Pharmaceuticals
      Health Care
    • SEC Form 15-12B filed by Five Prime Therapeutics, Inc.

      15-12B - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Filer)

      4/26/21 4:11:57 PM ET
      $FPRX
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Five Prime Therapeutics, Inc.

      EFFECT - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Filer)

      4/22/21 12:15:14 AM ET
      $FPRX
      Major Pharmaceuticals
      Health Care